Disease Markers

Disease Markers / 1994 / Article

Open Access

Volume 12 |Article ID 285298 | https://doi.org/10.1155/1994/285298

Peter L. Devine, Geoffrey W. Birrells, Jeffrey P. Golder, Michael N. Marsh, Shethah Morgan, Grace Chang, David Gillis, Peter Hobson, Peter Robertson, Ross Whybint, John H. Skerritt, "Screening and Monitoring Coeliac Disease: Multicentre Trial of a New Serum Antibody Test Kit", Disease Markers, vol. 12, Article ID 285298, 10 pages, 1994. https://doi.org/10.1155/1994/285298

Screening and Monitoring Coeliac Disease: Multicentre Trial of a New Serum Antibody Test Kit

Received30 Apr 1994

Abstract

A multicentre trial was conducted to evaluate a new test for anti-gliadin antibodies (AGA) in serum (Coeliac Screening Kit, CSK, Medical Innovations Limited, Artarmon, NSW, Australia). The te st showed excellent reproducibility for both anti-gliadin IgA and IgG detection. The average intraassay coefficient of variation (CV) was 3.0% for IgA and 2.4% for IgG (n=6), while the average interassay CV was 6.4% for IgA and 4.3% for IgG (n=3). By defining a positive te st as both IgA and IgG elevated, a sensitivity of 93% in untreated coeliacs (n=75) was observed. The corresponding specificities in healthy adults (n=130) and healthy children (n=77) were >99% and 100% respectively, while in patients with other gastrointestinal disorders (disease controls) the specificity was 94% (n=129). The test was also useful in monitoring patients, with anti-gliadin IgA and IgG falling for up to a year after commencing a gluten-free diet (GFD) (12 adults). In some patients however, antibody levels did not reach the normal cutpoint after many months on a GFD, which may reflect the patients ' poor adherence to their gluten free diet. The test was superior to the Pharmacia anti-gliadin ELISA, and should be useful as an aid to the diagnosis of coeliac disease, as well as in the follow-up of treated patients.

Copyright © 1994 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views68
Downloads371
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.